Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 5116 AL 5130

Advanced Glycation End Products in Neurodegenerative Diseases

Raghavan CT.

J Mol Neurosci. 2024 Dec 10;74(4):114. doi: 10.1007/s12031-024-02297-1.

Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases

Liu J, Mouradian MM.

Int J Mol Sci. 2024 Feb 17;25(4):2364. doi: 10.3390/ijms25042364.

The antisaccadic paradigm: A complementary neuropsychological tool in basal ganglia disorders

Hapakova L, Necpal J, Kosutzka Z.

Cortex. 2024 Sep;178:116-140. doi: 10.1016/j.cortex.2024.06.005. Epub 2024 Jun 22.

Experimental Cell Models for Investigating Neurodegenerative Diseases

Evangelisti C, Ramadan S, Orlacchio A, Panza E.

Int J Mol Sci. 2024 Sep 9;25(17):9747. doi: 10.3390/ijms25179747.

Heavy Metal Interactions with Neuroglia and Gut Microbiota: Implications for Huntington's Disease

Tizabi Y, Bennani S, El Kouhen N, Getachew B, Aschner M.

Cells. 2024 Jul 3;13(13):1144. doi: 10.3390/cells13131144.

Neurotoxicity of Pyrethroids in neurodegenerative diseases: From animals' models to humans' studies

Arsuffi-Marcon R, Souza LG, Santos-Miranda A, Joviano-Santos JV.

Chem Biol Interact. 2024 Mar 1;391:110911. doi: 10.1016/j.cbi.2024.110911. Epub 2024 Feb 15.

Pharmacogenomics for neurodegenerative disorders - a focused review

Ahmad SR, Zeyaullah M, Khan MS, AlShahrani AM, Altijani AAG, Ali H, Dawria A, Mohieldin A, Alam MS, Mohamed AOA.

Front Pharmacol. 2024 Dec 20;15:1478964. doi: 10.3389/fphar.2024.1478964. eCollection 2024.

Systemic Symptoms in Huntington's Disease: A Comprehensive Review

Mehanna R, Jankovic J.

Mov Disord Clin Pract. 2024 May;11(5):453-464. doi: 10.1002/mdc3.14029. Epub 2024 Mar 26.

A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease

Islam MR, Jony MH, Thufa GK, Akash S, Dhar PS, Rahman MM, Afroz T, Ahmed M, Hemeg HA, Rauf A, Thiruvengadam M, Venkidasamy B.

Mol Neurobiol. 2024 Mar;61(3):1237-1270. doi: 10.1007/s12035-023-03604-4. Epub 2023 Sep 12.

Using gene or cell therapies to treat Huntington's disease

Binda CS, Lelos MJ, Rosser AE, Massey TH.

Handb Clin Neurol. 2024;205:193-215. doi: 10.1016/B978-0-323-90120-8.00014-9.

Brain-Periphery Interactions in Huntington's Disease: Mediators and Lifestyle Interventions

Burtscher J, Strasser B, Pepe G, Burtscher M, Kopp M, Di Pardo A, Maglione V, Khamoui AV.

Int J Mol Sci. 2024 Apr 25;25(9):4696. doi: 10.3390/ijms25094696.

Cholesterol imbalance and neurotransmission defects in neurodegeneration

Shin KC, Ali Moussa HY, Park Y.

Exp Mol Med. 2024 Aug;56(8):1685-1690. doi: 10.1038/s12276-024-01273-4. Epub 2024 Aug 1.

Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders

Fatima J, Siddique YH.

CNS Neurol Disord Drug Targets. 2024;23(10):1217-1233. doi: 10.2174/0118715273283338240104112106.

Diagnostic and mechanistic roles of MicroRNAs in neurodevelopmental & neurodegenerative disorders

Khoodoruth MAS, Khoodoruth WNC, Uroos M, Al-Abdulla M, Khan YS, Mohammad F.

Neurobiol Dis. 2024 Nov;202:106717. doi: 10.1016/j.nbd.2024.106717. Epub 2024 Oct 24.

Dietary fasting and time-restricted eating in Huntington's disease: therapeutic potential and underlying mechanisms

Wells RG, Neilson LE, McHill AW, Hiller AL.

Transl Neurodegener. 2024 Apr 2;13(1):17. doi: 10.1186/s40035-024-00406-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias